Loading news...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs)
ACRES Commercial Realty (NYSE: ACR - Get Free Report) and AGNC Investment (NASDAQ: AGNCZ - Get Free Report) are both finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Analyst Recommendations This is a breakdown of
ACRES Commercial Realty Corp. (ACR) Q4 2025 Earnings Call Transcript
UNIONDALE, N.Y., March 4, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter and year ended December 31, 2025.
ACR Alpine Capital Research, LLC increased its stake in Arrow Electronics by 1,028,778 shares. Quarter-end position value rose by approximately $87 million, reflecting both trading activity and stock price movement.
KKR Real Estate Finance Trust (NYSE: KREF - Get Free Report) and ACRES Commercial Realty (NYSE: ACR - Get Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Institutional and Insider
UNIONDALE, N.Y., Feb. 18, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the fourth quarter 2025, on Wednesday, March 4, 2026, after the market closes.
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 4,780 shares of ACRES Commercial Realty stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $23.89, for a total transaction of $114,194.20. Following the completion of the transaction, the
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 692 shares of the company's stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $22.07, for a total transaction of $15,272.44. Following the transaction, the insider owned 754,699 shares of the
UNIONDALE, N.Y., Jan. 20, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced that its newly formed subsidiary, ACRES Commercial Realty 2026-FL4 Issuer, LLC (the "Issuer") will issue $879.5 million of non-recourse, floating-rate notes ("Offered Notes," the "Securities" or the "Offering") at a weighted-average cost of the one-month Term Secured Overnight Financing Rate ("SOFR")+168 basis points.
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 5,400 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $24.99, for a total value of $134,946.00. Following the completion of the sale, the insider
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 13,979 shares of the company's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $24.93, for a total transaction of $348,496.47. Following the completion of the sale, the insider directly owned
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low dose gemcitabine (ULDG) as a tumor sensitizer and enrollment completion expected in fourth quarter 2026 Based on preclinical AP3 data showing strong synergy between ACR-368 and anti-PD-L1, company has submitted a Phase 3 confirmatory protocol to the FDA for ACR-368 plus anti-PD-1 therapy in frontline EC subjects; global trial readiness expected mid-2026 Initial data from Phase 1 dose escalation (N=33) for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, showed favorable tolerability; two weekly oral dosing regimens (160 mg QD, 3d on/4d off and 240 mg QD, 2d on/5d off) established with a bi-weekly regimen initiated Tumor shrinkage was observed at ≥120 mg dose level in 9/20 subjects, including a confirmed PR in EC, and unconfirmed PRs in SCLC and sqNSCLC, two tumor types predicted sensitive by AP3, not previously shown sensitive to WEE1 inhibitors in development ACR-6840, a potential first-in-class AP3-derived oral CDK11 inhibitor, nominated as next preclinical development candidate, with IND submission planned for fourth quarter 2026 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026
ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) major shareholder Eagle Point Credit Management sold 5,000 shares of the business's stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $22.41, for a total value of $112,050.00. Following the sale, the insider owned 755,391 shares in the
Shares of ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026.
UNIONDALE, N.Y. , Dec. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.
ACRES Commercial Realty (NYSE: ACR - Get Free Report) and Cherry Hill Mortgage Investment (NYSE: CHMI - Get Free Report) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Volatility and Risk ACRES